Amanda Ryan, DO
Interventional Cardiology · Carlsbad, NMNPI 1689756595
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Philips North America LLC at 47.9% of the total. Reporting peaked in 2024 at $4,623 and has fallen 91.9% since, to $374 in 2025.
Across 187 payments — averaging $54.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$5K
- Medtronic$1K
- Terumo Medical Corporation$664
- Boston Scientific$652
- Abbott$336
- AstraZeneca$272
- plus $2K from 19 others
What the payments were for
- Consulting fees$2,82028%
- Travel & lodging$2,43824%
- Food & beverage$4,90248%
- Education$751%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 28 | $4,900 |
| Medtronic(2 entities) | 23 | $1,369 |
| Terumo Medical Corporation | 6 | $664 |
| Boston Scientific | 22 | $652 |
| Abbott | 7 | $336 |
| AstraZeneca | 17 | $272 |
| Abiomed | 3 | $248 |
| Johnson & Johnson | 9 | $247 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $240 |
| Novartis | 10 | $219 |
| E.r. Squibb & Sons, L.L.C. | 10 | $210 |
| Cordis US CORP. | 4 | $140 |
| Amgen | 5 | $126 |
| Pfizer | 6 | $112 |
| Tactile Systems Technology Inc | 7 | $111 |
| Astellas Pharma US Inc | 2 | $98 |
| Irhythm Technologies, Inc. | 3 | $72 |
| Davol Inc. | 1 | $52 |
| Bard Peripheral Vascular, Inc. | 1 | $36 |
| Amarin Pharma, Inc. | 2 | $33 |
| Inari Medical, Inc. | 1 | $25 |
| Novo Nordisk | 1 | $23 |
| Edwards Lifesciences | 1 | $20 |
| Boehringer Ingelheim | 1 | $16 |
| Scpharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (9520) IGT Devices Undivided$3,297
- Abre$791
- (6578) Visions 018$525
- GLIDESHEATH SLENDER$439
- Impella$147
- XIENCE SIERRA$133
- AZURE XT DR MRI SURESCAN$108
How this compares
$10,236 in reported general payments places this provider in the 65th percentile of 25 interventional cardiology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 486 | $369,066 |
| XareltoRivaroxaban | 269 | $238,469 |
| EntrestoSacubitril/Valsartan | 126 | $120,411 |
| Repatha SureclickEvolocumab | 63 | $43,977 |
| JardianceEmpagliflozin | 30 | $23,612 |
| BrilintaTicagrelor | 19 | $8,370 |
| Metoprolol Succinate | 675 | $7,696 |
| ClopidogrelClopidogrel Bisulfate | 659 | $6,515 |
| Atorvastatin Calcium | 562 | $4,847 |
| Losartan Potassium | 443 | $3,370 |
| Carvedilol | 600 | $3,351 |
| Potassium Chloride | 283 | $3,126 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 85 | $2,178 |
| Furosemide | 453 | $1,521 |
| Amlodipine Besylate | 369 | $1,485 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $112 | $369,066486 claims |
| Johnson & JohnsonXarelto | $247 | $238,469269 claims |
| NovartisEntresto | $219 | $120,411126 claims |
| Boehringer IngelheimJardiance | $16 | $23,61230 claims |
| AstraZenecaBrilinta | $272 | $8,37019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 25 interventional cardiology providers in New Mexico.
Other interventional cardiology in Carlsbad
- Mark BieniarzAlbuquerque$207K
- Raymond YauAlbuquerque$171K
- Robert FedericiAlbuquerque$77K
- Abdul KhanLas Cruces$23K
- Sharif HalimAlbuquerque$22K
- Geoffrey KunzAlbuquerque$22K
- Richard BlankenbakerFarmington$13K
- Ashley RiversRoswell$12K
- Charles KimAlbuquerque$9K
- Sudhakar GirotraFarmington$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.